Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Adalimumab/infliximab

New-onset atopic dermatitis and worsening of atopic dermatitis: 8 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Spencer EA, et al. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences 68 : 1121-1124, No. 4, Apr 2023. Available from: URL: https://www.springer.com/journal/10620 Spencer EA, et al. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences 68 : 1121-1124, No. 4, Apr 2023. Available from: URL: https://​www.​springer.​com/​journal/​10620
Metadaten
Titel
Adalimumab/infliximab
New-onset atopic dermatitis and worsening of atopic dermatitis: 8 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-43470-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Iohexol